capecitabine NDC 31722-774

NDC codes

FDA NDC Directory

Product NDC (as listed)31722-774Labeler and product segments. Claims need a package NDC.

Product NDC at billing width31722-0774Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
31722-774-60	31722077460	60 TABLET, FILM COATED in 1 BOTTLE (31722-774-60)Marketed from Mar 5, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): capecitabine
Generic name (nonproprietary): capecitabine
Active ingredients: Capecitabine — 150 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Camber Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210203
Marketing start: Mar 5, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 31722-774_519e85b4-ff10-917f-e063-6394a90a12dfSPL ID 519e85b4-ff10-917f-e063-6394a90a12dfSPL set ID 3e7d6317-1439-4976-ae00-6f62619ec3ddRxCUI 200327, 200328UNII 6804DJ8Z9UUPC 0331722775601, 0331722774604
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N431722077460 followed by a unit qualifier and the quantity

Package 31722-0774-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 12, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. ( 1.2 ) • treatment of patient…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210203

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210203
Product	Strength	Form · route	Labeler	Product NDC
capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-775
capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	NorthStar RxLLC	72603-303
Capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	BluePoint Laboratories	68001-644
Capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	BluePoint Laboratories	68001-643